secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2022-02-16T23:59:59+00:00
Accession:  0001493152-22-004799
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity Q3 FY22 revenue $1.93M (+93% YoY); net loss $7.34M, cash $16.8M
--------------------------------------------------------------------------

- Revenue of $1.93M, up 93% YoY and 7% sequentially; SG&A rose only 40%.
- Net loss $7.34M ($0.15/share); adjusted net loss $6.0M ($0.12/share) excluding $1.34M derivative expenses.
- Cash position of $16.8M at quarter-end is the highest ever; completed $12M non-dilutive debt financing.
- FDA clearance of Biotres expands TAM from $1B to $5.7B; Bioheart direct-to-consumer launched at $199.
- Company reiterates expectation for full-year triple-digit revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315222004799/0001493152-22-004799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315222004799/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-004799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer